Diagnostic Accuracy of the Indonesian-Adapted Chapron Questionnaire as a Non-Invasive Screening Tool for Endometriosis: A Cross-Sectional Diagnostic Test Accuracy Study

In: International Journal of Women's Health · 2026 · vol. Volume 18 , pp. 1–10 · doi:10.2147/ijwh.s630232 · W7225652179
Diagnostic accuracy OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-13 ⓘ

This study evaluated the diagnostic accuracy of the Indonesian-adapted Chapron questionnaire for endometriosis screening, finding that it demonstrated moderate sensitivity and specificity compared to histopathological results.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-13 · read from full text ⓘ

This cross-sectional study evaluated the diagnostic accuracy of an Indonesian-adapted Chapron questionnaire for screening endometriosis in 316 women undergoing gynecologic surgery at a tertiary hospital. Using histopathological results as the reference standard, researchers found that Score 2 achieved moderate sensitivity and specificity with an area under the curve of 0.739, indicating its potential utility as a non-invasive screening tool. The authors acknowledge that the study population consisted of surgical patients rather than primary care attendees, which may limit the generalizability of these findings to broader symptomatic populations. This paper is centrally about endometriosis — specifically focusing on validating a symptom-based screening instrument to reduce diagnostic delays in resource-limited settings.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: Endometriosis is a long-term systemic inflammatory disease that affects approximately 10% of women of reproductive age worldwide. The diagnosis of endometriosis often leads to delays of up to 11 years due to several obstacles, such as difficulty in diagnosing the condition, inaccurate beliefs, and self-management of symptoms. This delay results in an impaired quality of life, infertility, pain, sexual function, and diminished work productivity. Therefore, early screening of endometriosis is essential. Objective: To evaluate the diagnostic accuracy of the Indonesian-adapted Chapron symptom-based screening questionnaire by evaluating its sensitivity and specificity in relation to postoperative histopathological results. Methods: This cross-sectional diagnostic accuracy study was conducted at a gynecology outpatient clinic at a tertiary referral facility in Indonesia. Women who had undergone gynecologic surgery were enrolled, excluding those with suspected malignancy and pregnancy. Subjects has filled out a questionnaire after obtaining informed consent before. Histopathological analysis was performed as a reference standard. The sensitivity and specificity of both scores were calculated. The Youden index was used to determine the optimal cut-off using the receiver operating characteristic (ROC) curve. Results: A total of 316 women participated in this study. Score 1 (optimal cut-off > 16) had a sensitivity of 76.2% and a specificity of 59.2% (AUC 0.715). For score 2 (optimal cut-off > 14), the sensitivity of 74.3% and a specificity of 66.4% (AUC 0.739). At a cutoff value of > 16, score 1 showed a PPV of 48.2% and an NPV of 83.3%. Score 2, using a cutoff value of > 14, demonstrated slightly better predictive performance, with a PPV of 52.3% and an NPV of 83.8%. Conclusion: The Indonesian adaptation of Chapron’s screening questionnaire exhibits commendable diagnostic efficacy and may function as an effective non-invasive screening tool for identifying high-risk women with endometriosis in settings with limited resources to minimize diagnostic delays. Keywords: endometriosis, diagnosis, screening, symptom, questionnaire, Indonesia
Full text 35,563 characters · extracted from oa-doi-fallback · 12 sections · click to expand

Background

Endometriosis is a long-term systemic inflammatory disease that affects approximately 10% of women of reproductive age worldwide. The diagnosis of endometriosis often leads to delays of up to 11 years due to several obstacles, such as difficulty in diagnosing the condition, inaccurate beliefs, and self-management of symptoms. This delay results in an impaired quality of life, infertility, pain, sexual function, and diminished work productivity. Therefore, early screening of endometriosis is essential.

Objective

To evaluate the diagnostic accuracy of the Indonesian-adapted Chapron symptom-based screening questionnaire by evaluating its sensitivity and specificity in relation to postoperative histopathological results.

Methods

This cross-sectional diagnostic accuracy study was conducted at a gynecology outpatient clinic at a tertiary referral facility in Indonesia. Women who had undergone gynecologic surgery were enrolled, excluding those with suspected malignancy and pregnancy. Subjects has filled out a questionnaire after obtaining informed consent before. Histopathological analysis was performed as a reference standard. The sensitivity and specificity of both scores were calculated. The Youden index was used to determine the optimal cut-off using the receiver operating characteristic (ROC) curve.

Results

A total of 316 women participated in this study. Score 1 (optimal cut-off > 16) had a sensitivity of 76.2% and a specificity of 59.2% (AUC 0.715). For score 2 (optimal cut-off > 14), the sensitivity of 74.3% and a specificity of 66.4% (AUC 0.739). At a cutoff value of > 16, score 1 showed a PPV of 48.2% and an NPV of 83.3%. Score 2, using a cutoff value of > 14, demonstrated slightly better predictive performance, with a PPV of 52.3% and an NPV of 83.8%.

Conclusion

The Indonesian adaptation of Chapron’s screening questionnaire exhibits commendable diagnostic efficacy and may function as an effective non-invasive screening tool for identifying high-risk women with endometriosis in settings with limited resources to minimize diagnostic delays.

Keywords

endometriosis, diagnosis, screening, symptom, questionnaire, Indonesia

Introduction

Endometriosis is a long-term, systemic, and estrogen-dependent inflammatory disease that occurs when tissue that appears to be endometrial tissue grows outside of the uterus.1–3 It impacts approximately 10% of women of reproductive age worldwide, and up to 50% of those experiencing infertility or severe pelvic pain.1,2,4 The condition is a primary contributor to pelvic pain and infertility, associated with severe dysmenorrhea, dyspareunia, dyschezia, and chronic pelvic pain,3 which substantially lower health-related quality of life and work productivity.1,3,5,6 Despite extensive research, endometriosis remains a diagnostically elusive condition due to its heterogeneous clinical presentation, which frequently overlaps with other benign gynecological, gastrointestinal, and urinary disorders.7 The diagnostic delay, which is the time between the onset of symptoms and a certain diagnosis, is a big problem around the world, can take up to 11 years.1 These delays make diseases worse, make pain more sensitive, cause psychological suffering, and diminish women’s fertility.1,3,5 Delayed diagnosis has been demonstrated to exacerbate socioeconomic difficulties and healthcare costs.5,8 There are numerous reasons for delayed diagnosis of endometriosis. The delayed diagnosis of endometriosis is attributed to false beliefs and self-management, symptom heterogeneity, insufficient public and medical awareness, and the recognition of laparoscopy as the gold standard for diagnosis.2,3 At the individual level, there is a tendency to normalize menstruation discomfort, particularly throughout adolescence, frequently encouraged by cultural assumptions that dysmenorrhea is a normal part of being a woman.9 The prevalent symptoms of endometriosis, including pain, may be mistaken for other conditions. The symptoms of endometriosis are frequently atypical and mimic those associated with other gynecological, gastrointestinal, and urinary system disorders. The lack of specific symptoms at the primary care level, which can resemble irritable bowel syndrome (IBS) or interstitial cystitis, complicates the diagnosis of endometriosis, frequently results in misdiagnosis and inefficient symptomatic interventions.3 Moreover, the traditional dependence on laparoscopy with histological validation as the gold standard has resulted in a substantial obstacle. Surgery is invasive, expensive, has inherent risks, and is not easily accessible in numerous healthcare settings. This method is invasive, expensive, and impractical as an initial diagnostic or screening tool for symptomatic women. Noninvasive imaging techniques, including transvaginal ultrasound and magnetic resonance imaging, are beneficial.2 In spite of these barriers, there is increasing interest in creating non-invasive screening techniques to identify women at elevated risk for endometriosis and prioritize them for subsequent diagnostic assessment.2 In order to overcome diagnostic delay in endometriosis, Agarwal proposed a paradigm change in 2019 that suggested endometriosis may be diagnosed clinically.6 The European Society of Human Reproduction and Embryology’s 2022 guideline clarified this idea by stating that systematic history-taking and imaging can establish a clinical diagnosis, hence eliminating the need for surgical confirmation. However, transvaginal ultrasound and MRI require trained sonographer, radiologists, and equipment that are unavailable at the primary healthcare, particularly in Indonesia’s stratified referral system. A structured, symptom-based questionnaire can therefore serve as an accessible, low-cost first-line screening instrument to identify patients who need referral for further examination. To enable early detection and screening of individuals with probable endometriosis, the application of this clinical diagnostic technique necessitates effective, economical, and non-invasive screening instrument, such as standardized questionnaires.10 Chapron et al devised an adjusted clinical scoring method utilizing patient history and pain factors to predict endometriosis, with two complementary models: a comprehensive model incorporating a broader clinical variables, and an optimized model with a lesser variable designed for greater practicality in clinical settings. This integrative instrument integrates the intensity of dysmenorrhea, gastrointestinal symptoms, and surgical history.11 Nonetheless, symptom perception, healthcare-seeking behavior, and disease manifestation may vary among populations, indicating the need for local validation and adaptation, especially the cutoff of the scoring. In Indonesia, endometriosis is often underdiagnosed, and diagnostic laparoscopy is only available at tertiary referral hospitals.9 Currently, there is no validated symptom-based screening instrument for endometriosis adapted to the Indonesian population. Indonesia, an archipelago with a stratified healthcare system (BPJS Kesehatan), encounters distinct obstacles in its referral pathways. A validated instrument could enable general practitioners at the primary level (Puskesmas) to promptly recognize high-risk patients. This study aimed to overcome this issue by assessing the diagnostic accuracy of the Indonesian Version of Chapron’s Screening Method, comparing two modified scoring models as a screening tool for early detection of endometriosis in Indonesia, utilizing histopathological diagnosis as the reference standard.

Materials and methods

This diagnostic test accuracy study using a cross-sectional design was conducted at Dr. Hasan Sadikin General Hospital (RSHS), Bandung, West Java, Indonesia, between February 2025 and August 2025. RSHS is a tertiary hospital and referral center for advanced gynecological cases throughout West Java Province. Women who had undergone elective gynecological surgery for benign gynecological indications, were enrolled consecutively during the study period. We excluded patients with suspected malignancy prior to surgery, those currently pregnant, and those with malignancy. As the study population was women scheduled for surgery at a tertiary referral hospital, it carries a higher probability of endometriosis than in symptomatic community or primary healthcare population; this is addressed further as a limitation of the study (see Discussion). Before the study, the original Chapron questionnaire was subjected to a cultural adaptation process. The validated Indonesian version of the Chapron questionnaire was utilized. The questionnaire was shown on Appendix 1 (Indonesian version) and Appendix 2 (English translation).12 This prior publication (reference 12) reported the translation, adaptation, and validation of the Indonesian-version questionnaire itself; the present manuscript is a distinct, subsequent study that uses this previously adapted questionnaire to evaluate its diagnostic accuracy against a histopathological reference standard. Subjects self-administered the questionnaire regarding their condition before surgery, after obtaining informed consent regarding the research objectives, risks, and benefits of participating in the research. Histopathological evaluation of all surgical specimens was performed by pathologists, who were blinded to the participants’ questionnaire scores; surgeons were also blinded to the questionnaire scores, in order to minimize verification and review bias. We used two scoring systems derived from Chapron’s screening method (scores 1 and 2) in the questionnaire, as shown in Appendix 3. Score 1 (Comprehensive Model) = [(family history of endometriosis × 14) + (primary infertility × 6) + (BMI < 22 × 7) + (regular cycles < 28 days × 4) + (VAS dysmenorrhea ≥ 6 × 11) + (VAS dyspareunia ≥ 3 × 6)] + (VAS GI symptoms ≥ 5 × 14) + (VAS urinary tract symptoms ≥ 1 × 12). Score 2 (Optimized Clinical Model) = [(family history of endometriosis × 17) + (primary infertility × 5) + (BMI < 22 × 7) + (regular cycles < 28 days × 2) + (VAS dysmenorrhea ≥ 6 × 17)].11 Histopathological analysis of surgical specimens served as the reference standard. The minimum required sample size was calculated a priori using a diagnostic-accuracy sample-size formula comparing the AUC of the index test against the AUC of the reference standard: With a type I error of 5% (Zα = 1.96) and 90% power (Zβ = 1.64), an expected index-test AUC (AUC1) of 0.60, and a reference-standard AUC (AUC2) of 0.80, V1 and V2 were calculated as 0.153 and 0.098, respectively, yielding a minimum sample size of 95.13 After adjusting for a 10% anticipated dropout rate, the minimum required sample size was 105 participants, which was confirmed with the 316 participants enrolled in this study. Descriptive statistics were used to describe clinical characteristics. Sensitivity and specificity were measured for various cut-off thresholds of Scores I and II. Statistical analyses were performed using IBM SPSS Statistics (version 27.0; IBM Corp., USA) and Microsoft Excel version 16.55 (Microsoft Corp., USA). Diagnostic accuracy was evaluated by measuring the sensitivity and specificity for scores I, II, and endometriosis symptoms. Optimal cut-off points were employed using the Youden Index through the ROC curve, and the discriminative performance of each cut-off was quantified using the area under the curve (AUC) within the study. External validation would require testing the model on a completely separate, independent cohort, which was beyond the scope of the present study and is discussed as a limitation.

Results

In total, 316 patients were enrolled in the study. Histopathological analysis identified 105 patients with endometriosis and 211 without endometriosis. Table 1 shows the preliminary characteristics of the study population. A greater percentage of nulligravidas was noted among endometriosis patient (59.0% vs 40.3%; p = 0.02). Diagnostic table for each score can be seen in Appendix 3. | Table 1 Characteristic of Respondents | Patients in the endometriosis group demonstrated significantly more severe pain-related symptoms. The average VAS scores for dysmenorrhea, dyspareunia, gastrointestinal symptoms, and urinary tract symptoms were significantly higher in patients with endometriosis than in those without (p ≤ 0.001). Conversely, chronic pelvic pain exhibited no clinically significant differences between the two groups, despite statistical significance. The prevalence of each symptom is presented in Table 2. The measured parameter, VAS dysmenorrhea ≥6, showed a high prevalence of 70.5%. Dysmenorrhea, which disrupts daily activities showed the highest prevalence (76.2%). Menstrual syncope also showed significantly higher prevalence in endometriosis group (22.9%), compared to non-endometriosis group (5.2%; p <0.001). These results are consistent with previous studies that demonstrated severe dysmenorrhea as the most significant clinical manifestation of endometriosis and a crucial element in symptom-based diagnostic approaches.3,14–17 In consistent with previous studies showing that infertility is one of the most common clinical manifestations in affected individuals, this study showed primary infertility was 35.2% in endometriosis group compared with 18.5% in non-endometriosis group.18 | Table 2 Item Assessment of the Questionnaire Between Endometriosis and Non-Endometriosis Group | The diagnostic efficacy of the scoring models in differentiating patients with endometriosis from those without endometriosis was assessed using receiver operating characteristic (ROC) curve analysis. Figure 1 shows that score 1 had a moderate ability to distinguish the difference between groups, with an area under the curve (AUC) of 0.715 (95% confidence interval [CI]: 0.662–0.764), which was statistically significant (p 16, determined using the Youden index, with a sensitivity of 76.2% and a specificity of 59.2%. Similarly, ROC analysis for score 2 showed a slightly improved diagnostic performance, with an AUC of 0.739 (95% CI: 0.687–0.786; p 14, corresponding to a sensitivity of 74.3% and a specificity of 66.4%. Both scores demonstrated acceptable internal discrimination within the study, with AUC values >0.700. A formal statistical comparison between the two ROC curves was not performed in this analysis; therefore, the small numerical difference in AUC between score 1 (0.715) and score 2 (0.739) cannot be considered statistically superior to the other, and can be considered to be done in the future studies. The analysis showed that for Score 1, at a cut-off value of >16, the positive predictive value (PPV) was 48.2%. In contrast, the negative predictive value (NPV) was 83.3%, suggesting a relatively strong ability to screen non-endometriosis patients. For Score 2 at a cutoff value of >14, the PPV increased to 52.3%, reflecting a modest improvement in the ability to screen endometriosis patient. The NPV also showed a slightly increase to 83.8%. For the likelihood ratio (LR), score 1 (>16) showed an LR+ of 1.87 and LR− of 0.40, while Score 2 (>14) demonstrated slightly better performance, with an LR+ of 2.21 and LR− of 0.39. As PPV and NPV are inherently dependent on disease prevalence, these values were calculated within a tertiary healthcare with a relatively high prevalence of endometriosis (33.2%), which is higher than the prevalence in primary care or community population. Consequently, the PPV and NPV reported may not be directly transferable to primary care settings, where likelihood ratios provide a more prevalence-independent measure of diagnostic performance. Figure 3 shows the predicted distribution of endometriosis scores of 1 and 2. As the score values increased, both scoring models showed a steady increase in the predicted probability. This shows that the scoring system and the likelihood of endometriosis are closely correlated. Score 2 exhibited a more pronounced rise in predicted probability relative to score 1, indicating a stronger and more selective gradient among the score levels. Within comparable score ranges, score 2 generally yielded an elevated predicted probability, particularly in the mid-to-high score intervals. This trend suggests that a score of 2 may more effectively distinguish individuals at an elevated risk of endometriosis. While both models exhibited consistent trends, the more pronounced trajectory in score 2 indicated that this model may offer enhanced risk distinction at higher score values.

Discussion

This research demonstrates the Indonesian adaptation of Chapron’s screening tool within a tertiary healthcare setting in Indonesia. Both modified scoring systems had sensitivities exceeding 70% at optimum cutoff thresholds, signifying satisfactory efficacy for screening rather than definitive diagnosis. These results align with the original validation by Chapron et al, who reported sensitivities between 75–80%,11 as well as subsequent validations in various populations, including Europe, United States, Australia, and Middle-East Asia. The consistency of these findings across diverse ethnic groups underscores the generality of endometriosis symptoms despite cultural differences in the expression of pain.19,20 The novelty of this study lies primarily in its contextual and epidemiological adaptation of an existing diagnostic instrument, rather than in the development of an entirely new screening tool. By validating two Chapron-derived scoring models specifically within the Indonesian population, addresses a practical and meaningful gap for low- and middle-income countries with stratified healthcare systems, where locally validated, low-cost screening tools are needed to guide referral decisions in the absence of easily accessible imaging or specialist expertise. In Indonesia, where patients may be hesitant to address sexual health issues (dyspareunia) due to cultural taboos, family history acts as an objective, non-stigmatized indicator.9 In this study, the prevalence of a family history of endometriosis is greater in endometriosis patient (18.1%) compared to the non-endometriosis patient (8.1%). The significant emphasis on severe dysmenorrhea highlights the high occurrence of “loss of consciousness” (prevalence 22.86%) with endometriosis patient, compared to non-endometriosis patients (5.2%). This indicates a pronounced vasovagal reaction to vigorous prostaglandin-induced uterine contractions and peritoneal inflammation. The high incidence of severe dysmenorrhea in endometriosis patients in our study aligns with previous research that has acknowledged dysmenorrhea intensity as a reliable clinical indicator of the disease.3,14–17 This suggests that screening algorithms should include the severity of pain, not just the fact that it is present. Clinically, this suggests that, in Indonesia, any patient experiencing monthly syncope should be considered at a high risk for endometriosis unless proven otherwise. We have a modest specificity of 59.2% for score 1, and 66.4% for score 2. It is essential to analyze this within the limitations of the study setting. The non-endometriosis group consisted of women who underwent surgery for gynecological problems, such as symptomatic leiomyomas, adenomyosis, or ovarian cysts, rather than healthy women. These disorders frequently exhibit overlapping symptoms, including pelvic bleeding and irregular bleeding. For example, 29.38% of non-endometriosis group exhibited VAS ≥ 6 dysmenorrhea. This “clinical noise” affects differentiation more than it does in a healthy group. This illustrates the actual issue encountered by clinicians: differentiating endometriosis from other gynecological disorders rather than from the health itself. Consequently, a specificity of 66% within the surgical population is particularly significant for a questionnaire-based tool. If performed in the general female population, this may produce a higher specificity value. This can be applied in further studies. The current study revealed that both scoring systems showed a moderate ability to detect endometriosis (sensitivity 76.2% and specificity 59.2% for score 1 at cutoff >16 and sensitivity 74.3% and specificity 66.4% for score 2 at cutoff >14). Our results showed a generally similar diagnostic performance with moderate sensitivity and specificity across both score systems when compared to the original study by Chapron et al (sensitivity 73% and specificity 75% for score 1 at cutoff ≥18 and sensitivity 78% and specificity 62% for score 2 at cutoff ≥17). However, lower optimal cut-off values were found in the Indonesian population (>16 vs ≥18 for Score 1 and >14 vs ≥17 for Score 2).11 This shift may indicate cross-cultural differences in symptom reporting, questionnaire item interpretation, or underlying population characteristics, underscoring the significance of local validation prior to clinical implementation. Both scores 1 and score 2 showed superior efficacy in excluding the condition, as evidenced by consistently elevated NPV values (83.3% for score 1 at cutoff >16 and 83.8% for score 1 at cutoff >14), compared to their ability to confirm its presence, indicated by moderate PPV values (48.2% for score 1 at cutoff >16 and 52.3% for score 1 at cutoff >14). As noted above, both the PPV and NPV were derived from a tertiary healthcare with a comparatively high endometriosis prevalence. Because these are prevalence-dependent, these should be interpreted with caution if the questionnaire is applied in primary care or community settings with a lower expected prevalence. The slightly higher LR+ observed in score 2 suggests a better ability to increase the probability of endometriosis following a positive test result. However, both scores had comparatively low LR+ values, suggesting a limited utility for diagnosis confirmation. Conversely, LR− values of approximately 0.40 in both models suggest a moderate ability to reduce the probability of endometriosis following a negative result, suggesting that the Indonesian-adapted Chapron Questionnaire may serve as a screening tool rather than a confirmatory tool. Calibration of the predicted probabilities, and a formal decision-curve analysis of clinical net benefit at plausible primary care prevalence levels, were not performed, and are recommended for future work to more directly demonstrate the clinical usefulness of the questionnaire in that setting. Our research confirmed that endometriosis is not a uterine problem. The incidence of gastrointestinal symptoms (painful defecation ≥5) was twice as high in endometriosis patient (32.4%) compared to those without (15.2%). This underscores the prevalence of posterior cul-de-sac involvement or rectal closeness resulting in cyclic dyschezia. The incorporation of non-gynecological symptoms is the principal advantage of Chapron’s method compared to basic unidimensional pain scales.11 Indonesia has a hierarchical referral system. Presently, numerous women with endometriosis remain in primary care and receive analgesics only for extended periods. Physicians and non-gynecological specialists have reported difficulties in diagnosing endometriosis symptoms due to the variability of these symptoms.21,22 Because the present study was conducted exclusively in a tertiary healthcare, routine implementation of this questionnaire in Indonesian primary care would be premature. We propose it as a candidate instrument for prospective validation at the primary healthcare (Puskesmas) level. If future studies confirm adequate performance in that setting, women identified as high risk could be referred for transvaginal ultrasound (TVUS). Such a staged strategy would allow the most effective use of limited advanced facilities, such as transvaginal ultrasound or magnetic resonance imaging (MRI), for high-probability cases, promoting the earlier detection of endometriosis. The strengths of this study are the utilization of histopathology as the definitive gold standard for all participants (thereby limiting verification bias), the blinding of surgeons and pathologists to scores, and the assessment of the two scoring models. This study had several limitations. As a tertiary center study, the prevalence of serious diseases is presumably elevated compared to that in the general population. This may overestimate the sensitivity, specificity, and predictive values reported relative to what would be observed if the questionnaire were applied at the primary healthcare level. The specific focus on surgical patients may restrict generalizability to community or primary care groups. The AUC-based assessment reported here reflects internal discrimination rather than external validation, which acknowledged as methodological limitations. Adenomyosis was not rigorously excluded from the non-endometriosis group in the absence of endometriosis, potentially weakening the specificity owing to overlapping symptoms. Recall bias could have affected this study because self-reported questionnaires were used to collect data on a number of variables, and subject recall their condition, especially pain, before the surgery. Future prospective cohort studies with independent-cohort external validation, and enrollment in more diverse groups are essential, such as in the primary care population.

Conclusion

The validated Indonesian adaptation of Chapron’s screening method for endometriosis demonstrated satisfactory diagnostic performance for both scoring models. Score 1, at a threshold of >16, achieved a sensitivity of 76.2% and a specificity of 59.2%, while score 2, at a threshold of >14, achieved a sensitivity of 74.3% and a specificity of 66.4%, together with a numerically higher AUC (0.739 vs 0.715) and LR+ (2.21 vs 1.87). Score 2 may represent a more pragmatic choice for primary care implementation, given its comparable sensitivity, slightly better specificity and AUC, and shorter, more practical variable set. Both scores showed high NPV (83.3% for score 1 at cutoff >16, and 83.8% for score 2 at cutoff >14), reflecting superior efficacy in excluding endometriosis compared to their ability to confirm its presence, as indicated by moderate PPV values (48.2% for score 1 at cutoff >16, and 52.3% for score 2 at cutoff >14). As these predictive values are prevalence-dependent, they should be reinterpreted if the tool is applied in lower-prevalence primary care settings. The research also revealed that dysmenorrhea, which interferes with daily activities, and menstrual syncope, serve as good indicators of endometriosis in this population. This study was conducted exclusively in a tertiary surgical population, we suggest that this tool be prospectively validated in primary care and community settings before being incorporated into routine reproductive health screening. If such validation confirms adequate performance, the questionnaire could help close the diagnostic gap, enable earlier medical treatment, and help preserve Indonesian women’s fertility by identifying high-risk patients early, without the need for immediate surgery. Ethical Approval This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of Padjadjaran University approval number 292/UN6.KEP/EC/2026, dated April 15th 2026. The ethics committee reviewed and approved the study protocol. Informed consent was obtained from all subjects included in this study. Acknowledgments This publication charge is funded by Unpad through the Indonesian Endowment Fund for Education (LPDP) on behalf of the Indonesian Ministry of Higher Education, Science, and Technology and managed under the EQUITY Program (Contract No. 4303/B3/DT.03.08/2025 and 3927/UN6. RKT/HK.07.00/2025). Author Contributions All authors contributed significantly to the work reported, whether it was in the conception, study design, execution, data collection, analysis, and interpretation, or in all of these areas; participated in the article’s drafting, revision, or critically reviewing the article; gave final approval of the version to be published; agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work. Funding There is no funding to report. Disclosure There is no conflict of interest in this work.

References

1. Davenport S, Smith D, Green DJ. Barriers to a timely diagnosis of endometriosis: a qualitative systematic review. Obstet Gynecol. 2023;142(3):571–10. doi:10.1097/AOG.0000000000005255 2. Kim MR, Chapron C, Romer T, et al. Clinical diagnosis and early medical management for endometriosis: consensus from Asian expert group. Healthc. 2022;10(12):2515. doi:10.3390/healthcare10122515 3. Allaire C, Bedaiwy MA, Yong PJ. Diagnosis and management of endometriosis. CMAJ. 2023;195(10):E363–E71. doi:10.1503/cmaj.220637 4. Chauhan S, More A, Chauhan V, Kathane A. Endometriosis: a review of clinical diagnosis, treatment, and pathogenesis. Cureus. 2022;14(9):e28864. doi:10.7759/cureus.28864 5. Muharam R, Amalia T, Pratama G, et al. Chronic pelvic pain in women with endometriosis is associated with psychiatric disorder and quality of life deterioration. Int J Womens Health. 2022;14:131–138. 6. Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019;220(4):354 e1–e12. 7. Quesada J, Harma K, Reid S, et al. Endometriosis: a multimodal imaging review. Eur J Radiol. 2023;158:110610. 8. Ellis K, Munro D, Clarke J. Endometriosis is undervalued: a call to action. Front Glob Womens Health. 2022;3:902371. doi:10.3389/fgwh.2022.902371 9. Harzif AK, Anisa BM, Suarthana E, et al. Patient-centered endometriosis care implementation at tertiary and secondary care hospitals in Indonesia. Heliyon. 2024;10(21):e39914. 10. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022:20–34. 11. Chapron C, Lafay-Pillet MC, Santulli P, et al. A new validated screening method for endometriosis diagnosis based on patient questionnaires. EClinicalMedicine. 2022;44:101263. doi:10.1016/j.eclinm.2021.101263 12. Hendrana ARA, Tjahyadi D, Bayuaji H, Rachmawati A, Prasetyo NE, Djuwatono T. The Indonesian version of the Chapron’s screening method for endometriosis diagnosis based on questionnaire as a tool for better endometriosis screening in Indonesia. Indones J Obstet Gynecol Sci. 2025;8(2):284–293. doi:10.24198/obgynia.v8i2.890 13. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inf. 2014;48:193–204. doi:10.1016/j.jbi.2014.02.013 14. Gkrozou F, Tsonis O, Sorrentino F, et al. Endometriosis predictive models based on self-assessment questionnaire, evidence from clinical examination or imaging findings: a narrative review. J Clin Med. 2024;13(2):356. doi:10.3390/jcm13020356 15. Ortega-Gutierrez M, Munoz-Gamez A, Giron-Prieto MS. Primary care approach to endometriosis: diagnostic challenges and management strategies-a narrative review. J Clin Med. 2025;14(13):4757. 16. Sankaravadivel V, Thalavaipillai S. Symptoms based endometriosis prediction using machine learning. Bull Electr Eng Inf. 2021;10(6):3102–3109. doi:10.11591/eei.v10i6.3254 17. De Corte P, Klinghardt M, von Stockum S, Heinemann K. Time to diagnose endometriosis: current status, challenges and regional characteristics-a systematic literature review. BJOG. 2025;132(2):118–130. 18. Zhang B, Lv X, Li D, Zhang L, Ru Z, Ma Y. Diagnostic accuracy of machine learning for endometriosis: a systematic review and meta-analysis. Front Endocrinol. 2025;16:1735567. 19. Goldstein A, Cohen S. Self-report symptom-based endometriosis prediction using machine learning. Sci Rep. 2023;13(1):5499. doi:10.1038/s41598-023-32761-8 20. Zielinski K, Drabczyk D, Kunicki M, Drzyzga D, Kloska A, Ruminski J. Evaluating the risk of endometriosis based on patients’ self-assessment questionnaires. Reprod Biol Endocrinol. 2023;21(1):102. doi:10.1186/s12958-023-01156-9 21. Amro B, Ramirez Aristondo ME, Alsuwaidi S, et al. New understanding of diagnosis, treatment and prevention of endometriosis. Int J Environ Res Public Health. 2022;19(11):6725. doi:10.3390/ijerph19116725 22. van der Zanden M, de Kok L, Nelen W, Braat DDM, Nap AW. Strengths and weaknesses in the diagnostic process of endometriosis from the patients’ perspective: a focus group study. Diagnosis. 2021;8(3):333–339. doi:10.1515/dx-2021-0043 © 2026 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. Recommended articles Sex Differences in the International Primary Care Airways Group Questionnaire for Screening of Chronic Obstructive Pulmonary Disease: A Retrospective, Cross-Sectional Study Machiguchi H, Arizono S, Tawara Y, Oomagari M, Yanagita Y, Tanaka T, Senjyu H, Kozu R International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1467-1476 Published Date: 22 June 2022 Autism Spectrum Disorder Diagnoses: A Comparison of Countries with Different Income Levels Matos MB, Bara TS, Cordeiro ML Clinical Epidemiology 2022, 14:959-969 Published Date: 13 August 2022 Prenatal Diagnosis of Retinoblastomas: A Scoping Review Rodriguez A, Kelley C, Patel A, Ramasubramanian A International Journal of General Medicine 2023, 16:1101-1110 Published Date: 27 March 2023 A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements Yalcin S, Lacin S, Kaseb AO, Peynircioğlu B, Cantasdemir M, Çil BE, Hurmuz P, Doğrul AB, Bozkurt MF, Abali H, Akhan O, Şimşek H, Sahin B, Aykan FN, Yücel İ, Tellioğlu G, Selçukbiricik F, Philip PA Journal of Hepatocellular Carcinoma 2024, 11:953-974 Published Date: 29 May 2024 The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways Beckman KA, Syed ZA, Gromacki SJ Therapeutics and Clinical Risk Management 2026, 22:580025 Published Date: 5 June 2026

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Source provenance

openalex
last seen: 2026-11-16T06:03:07.005966+00:00
License: CC0 · commercial use OK